Matinas Biopharma
MTNBMTNB · Stock Price
Historical price data
Overview
Matinas BioPharma's mission is to overcome critical drug delivery challenges through its Lipid Nano-Crystal (LNC) platform, which facilitates oral, intracellular delivery of complex therapeutics. Its primary achievement is the advancement of MAT2203, an oral formulation of the potent but toxic antifungal amphotericin B, into Phase 2/3 clinical development with multiple FDA designations. The company's strategy involves advancing its internal pipeline in infectious disease and inflammation while seeking partnerships to leverage its LNC platform across broader therapeutic areas, including oncology and oligonucleotide delivery.
Technology Platform
The Lipid Nano-Crystal (LNC) platform uses natural, non-toxic cochleates to enable the safe, targeted, oral, and intracellular delivery of challenging therapeutics, including toxic small molecules and small oligonucleotides like siRNA and ASOs.
Pipeline
10| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Placebo + MAT9001 (omega-3 pentaenoic acid) | Severe Hypertriglyceridemia | Phase 3 | |
| MAT2203 + Amphotericin B | Cryptococcal Meningitis | Phase 3 | |
| Oral Encochleated Amphotericin B (CAMB) | Acute Myeloid Leukemia | Phase 2 | |
| Amphotericin B | Candidiasis, Chronic Mucocutaneous | Phase 2 | |
| Omega 3 pentaenoic acid + icosapent ethyl | Hypertriglyceridemia | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
MAT2203 competes with IV amphotericin B formulations and newer antifungals, differentiating on oral administration and potential safety. The LNC platform competes with other advanced delivery technologies (e.g., LNPs); its key differentiators are oral bioavailability for intracellular delivery and a natural lipid composition.